CEO of Invion outlines route to parity in valuation among peers, as escalating momentum for cancer treatment trials is noted
=====================================================================
In a recent statement, Thian Chew, the Executive Chair and CEO of Invion, has suggested that by addressing three near-term priorities, the company could achieve comparable valuations to other clinical-stage oncology companies.
Invion's platform therapy is currently in the clinical trial stage for the treatment of certain types of cancer, including prostate cancer, non-melanoma skin cancer, and anogenital cancer. The therapy is being tested across multiple types of cancer, with Invion working alongside the National Cancer Center Hospital East in Japan to test its PhotoDynamic Therapy.
Chew believes that simplifying licensing, cleaning up shareholder financing structures, and increasing investor awareness are crucial steps in attracting investment and increasing Invion's valuation. He stated that these priorities could create "interesting opportunities" for Invion without needing further development work.
The company has already received an orphan drug designation from the US Food and Drug Administration, which may potentially fast track approvals. Treatment costs for cancer often hover around US$300,000, making an effective and affordable treatment a significant need.
Chew also emphasized the importance of addressing unmet needs in cancer treatment for Asian populations, as approximately 60% of the world's population lives in Asia. He believes that there is a significant priority for Invion to focus on cancer treatment in Asian populations, as only 6% of patients involved in US drug development are Asian.
Invion (ASX:IVX) sees a potential rerate toward clinical-stage oncology peer valuations, ranging from AU$30 million to AU$40 million up to several hundred million. With a focus on simplifying operations, increasing investor awareness, and addressing the needs of Asian populations, Invion is poised to make a significant impact in the field of oncology.
However, Chew acknowledges that making people invest time to understand Invion's progress is a key challenge. He encourages those interested in Invion's work to stay informed and engaged as the company continues to make strides in the clinical trial stage and beyond.
Read also:
- Early Onset Puberty: Its Definition, Triggers, Risks, and Managing Strategies
- "Satanic Worship Owns the Spotlight in America: QAnon Spurring Modern Day Satanic Panic"
- A discussion about the nature of congenital syphilis, a medical condition that occurs when a pregnant woman who has syphilis passes the infection to her baby during childbirth or through the placenta during pregnancy.
- Significant Breakthroughs in Humankind's Origins: Highlighting the Pivotal Developments in Human Evolution During 2018
